No Data
Express News | Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Verve Therapeutics Names Lister as Chief Scientific Officer
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing me
Verve Therapeutics Announces Leadership Update
Troy Lister, Ph.D., to be promoted to chief scientific officerAndrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve
Verve Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing me
Verve Therapeutics Slides As Insider Purchases Lose Another US$55k
The recent price decline of 11% in Verve Therapeutics, Inc.'s (NASDAQ:VERV) stock may have disappointed insiders who bought US$475.8k worth of shares at an average price of US$6.26 in the past 12 mont